International Journal of
ADVANCED RESEARCH & INNOVATIONS

Volume 14, Issue-12
December, 2024, P20
ISSN: 2319-9253

AUTONOMOUS PRECISION ONCOLOGY: THE CONVERGENCE OF FOUNDATION AI MODELS, DIGITAL TWINS, AND COMPUTATIONAL CANCER INTELLIGENCE

[#1] **Dr. Nirmal Raj**, Professor, Department of General Medicine,
SRM Medical College Hospital and Research Centre, Chennai, India
Nirmalraj79@gmail.com

Abstract: Autonomous precision oncology represents the next evolutionary stage of computational cancer medicine, where foundation artificial intelligence (AI) models, digital twins, multimodal learning, and computational cancer intelligence converge to create continuously adaptive clinical ecosystems capable of supporting personalized diagnosis, prognostic prediction, therapeutic optimization, and longitudinal disease management. Conventional oncology frequently relies on fragmented diagnostic workflows, episodic clinical assessments, and isolated interpretation of imaging, pathology, molecular diagnostics, and clinical information, limiting comprehensive understanding of the dynamic biological evolution of cancer. Recent advances in foundation AI models, multimodal transformer architectures, graph neural networks, self-supervised learning, reinforcement learning, and generative artificial intelligence have enabled unified analysis of radiological imaging, digital pathology, genomics, transcriptomics, proteomics, metabolomics, epigenomics, spatial biology, laboratory biomarkers, circulating tumor DNA, wearable physiological monitoring, electronic health records, and longitudinal clinical outcomes. These intelligent computational systems support early cancer detection, biomarker discovery, molecular characterization, prognostic prediction, therapeutic optimization, immunotherapy selection, digital twin simulation, adaptive disease monitoring, and intelligent clinical decision support. Emerging technologies including multimodal large language models, federated learning, retrieval-augmented generation, explainable artificial intelligence, and agentic AI further strengthen autonomous oncology by enabling collaborative, privacy-preserving, transparent, and continuously adaptive biomedical reasoning. Despite remarkable technological advances, important scientific, technical, ethical, and regulatory challenges remain regarding multimodal data harmonization, computational scalability, interpretability, interoperability, cybersecurity, clinical validation, and equitable implementation. This review provides a comprehensive overview of autonomous precision oncology, emphasizing the convergence of foundation AI models, digital twins, and computational cancer intelligence as a transformative paradigm for next-generation personalized cancer medicine.[1]

Keywords: *Autonomous oncology, Foundation models, Artificial intelligence, Digital twins, Computational oncology, Precision medicine, Clinical intelligence, Multi-omics, Personalized cancer care, Clinical decision support.*

1. Introduction

Cancer is a biologically dynamic disease characterized by continuous genomic evolution, epigenetic remodeling, immune adaptation, metabolic reprogramming, angiogenesis, tissue remodeling, and intricate interactions among malignant cells, stromal components, immune populations, and host physiology. These interconnected biological processes evolve throughout diagnosis, treatment, recurrence, metastasis, and survivorship, making precision oncology increasingly dependent upon computational systems capable of integrating heterogeneous biomedical information across multiple biological scales.[2]

Modern oncology routinely generates enormous quantities of biomedical information through radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, epigenomics, spatial biology, laboratory investigations, circulating tumor DNA, wearable physiological monitoring, physician documentation, electronic health records, and patient-reported outcomes. Although each modality contributes valuable biological insight, isolated interpretation frequently overlooks systems-level relationships governing disease progression, therapeutic response, resistance mechanisms, and long-term clinical outcomes.[3]

Artificial intelligence has emerged as a transformative computational technology capable of integrating these heterogeneous biomedical datasets into unified patient-centered representations. Foundation AI models provide generalized biomedical reasoning, digital twins create continuously evolving virtual patients, and computational cancer intelligence enables adaptive knowledge generation from multimodal healthcare data.

The convergence of these technologies establishes autonomous precision oncology as a transformative computational framework capable of continuously improving personalized cancer care.[4]

2. Evolution of Autonomous Precision Oncology

Computational oncology has evolved from conventional statistical analyses toward intelligent biomedical ecosystems capable of continuously learning from multimodal healthcare information. Early machine learning approaches primarily relied upon handcrafted feature engineering and task-specific predictive algorithms developed for isolated diagnostic or prognostic applications. Although these systems demonstrated clinical value, they remained constrained by fragmented biomedical information, limited adaptability, and narrow generalizability.[5]

Deep learning substantially advanced computational oncology through automated representation learning from radiological imaging, digital pathology, genomic sequencing, and electronic health records. Transformer architectures subsequently revolutionized biomedical artificial intelligence by enabling generalized contextual learning across heterogeneous biomedical modalities.

Foundation AI models now acquire transferable biomedical knowledge through large-scale self-supervised pretraining, while reinforcement learning, multimodal large language models, digital twins, federated learning, and agentic AI have established autonomous computational ecosystems capable of continuously adapting to evolving biomedical evidence and patient-specific disease trajectories.[6]

3. Principles of Autonomous Foundation AI Models

Autonomous foundation AI models differ fundamentally from conventional artificial intelligence because they acquire generalized biomedical representations from massive multimodal datasets before specialization for individual oncology applications while continuously refining computational knowledge during clinical deployment. Rather than learning isolated predictive tasks, these models develop transferable computational intelligence applicable across diagnosis, prognosis, molecular characterization, biomarker discovery, therapeutic optimization, disease monitoring, computational pathology, radiomics, immunotherapy, and clinical decision support.[7]

Self-supervised learning enables discovery of latent biological relationships without requiring extensive manual annotation, while multimodal transformer architectures align radiological imaging, digital pathology, genomics, transcriptomics, proteomics, metabolomics, laboratory biomarkers, wearable physiological monitoring, physician documentation, patient-reported outcomes, and longitudinal clinical trajectories within unified computational embedding spaces.

Graph neural networks, reinforcement learning, and continual learning algorithms further enable autonomous reasoning by modeling interactions among genes, proteins, signaling pathways, immune populations, imaging phenotypes, tissue architecture, therapeutic targets, physiological variables, and clinical outcomes.[8]

4. Computational Architecture

Modern autonomous precision oncology platforms consist of interconnected computational layers

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv14i1220

responsible for biomedical data acquisition, preprocessing, representation learning, multimodal fusion, autonomous reasoning, adaptive learning, predictive analytics, digital twin simulation, and intelligent clinical decision support.[9]

The acquisition layer continuously integrates radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, epigenomics, spatial biology, laboratory investigations, circulating tumor DNA, wearable physiological monitoring, medication history, physician documentation, patient-reported outcomes, and electronic health records. Advanced preprocessing pipelines normalize imaging studies, harmonize molecular datasets, encode clinical narratives using natural language processing, and synchronize temporal patient information.

Foundation AI models subsequently generate generalized multimodal embeddings representing molecular biology, tissue architecture, imaging phenotypes, physiological function, and longitudinal clinical trajectories. These unified computational representations continuously evolve through autonomous learning while supporting predictive precision oncology.[10]

5. Foundation AI Models as Computational Cancer Intelligence

Foundation AI models constitute the computational intelligence underlying autonomous oncology because they acquire generalized biomedical knowledge from massive multimodal datasets before specialization for individual clinical applications. Unlike conventional task-specific algorithms, foundation models develop transferable computational representations applicable across diagnosis, prognosis, biomarker discovery, therapeutic prediction, disease monitoring, radiomics, computational pathology, immunotherapy, and intelligent clinical decision support.[11]

Transformer architectures enable multimodal attention across imaging, pathology, molecular biology, laboratory investigations, wearable monitoring, and clinical documentation, while graph neural networks characterize interactions among signaling pathways, immune responses, imaging phenotypes, therapeutic targets, physiological variables, and longitudinal clinical outcomes.

These generalized computational capabilities establish foundation AI models as continuously evolving biomedical reasoning systems supporting autonomous precision oncology.[12]

6. Multimodal Biomedical Intelligence

Comprehensive autonomous oncology depends upon seamless integration of complementary biomedical modalities into unified patient-specific computational representations. Radiological imaging provides anatomical and functional characterization of tumors, digital pathology reveals microscopic tissue architecture, and multi-omics technologies—including genomics, transcriptomics, proteomics, metabolomics, epigenomics, immunomics, microbiomics, and spatial biology—offer comprehensive molecular characterization of evolving cancer biology.[13]

Wearable biosensors continuously monitor physiological parameters including heart rate, sleep quality, physical activity, medication adherence, treatment-related symptoms, and quality-of-life indicators, while electronic health records contribute longitudinal clinical context extending across diagnosis, treatment, recurrence, and survivorship.

Artificial intelligence harmonizes these diverse biomedical modalities using multimodal transformers, graph neural networks, biological knowledge graphs, and cross-modal attention mechanisms capable of generating adaptive computational embeddings representing continuously evolving patient biology.[14]

7. Digital Twins and Autonomous Virtual Patients

Digital twin technology represents one of the defining components of autonomous precision oncology by creating continuously evolving computational replicas of individual cancer patients synchronized with their biological counterparts. Foundation AI models integrate serial radiological imaging, digital pathology, genomics, transcriptomics, proteomics, metabolomics, laboratory biomarkers, circulating tumor DNA, wearable physiological monitoring,

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv14i1220

medication history, patient-reported outcomes, and longitudinal clinical information into adaptive computational patient models capable of simulating disease progression, therapeutic response, treatment-related toxicity, recurrence, metastatic dissemination, and survival.[15]

Unlike conventional predictive models, digital twins continuously update their computational representations as new biomedical information becomes available. These intelligent virtual patients enable clinicians to evaluate multiple therapeutic strategies before implementation, optimize treatment sequencing, anticipate mechanisms of therapeutic resistance, and personalize supportive care according to evolving patient biology.

Digital twins therefore establish a predictive computational environment supporting proactive rather than reactive cancer care.[16]

8. Real-Time Autonomous Clinical Intelligence

A defining characteristic of autonomous precision oncology is the generation of real-time clinical intelligence through continuous integration of evolving biomedical information. Foundation AI models analyze serial imaging examinations, computational pathology, circulating tumor DNA, laboratory biomarkers, wearable physiological monitoring, physician documentation, medication history, patient-reported outcomes, and longitudinal clinical trajectories while continuously updating individualized disease representations.[17]

Unlike traditional clinical decision-support systems that rely upon periodic reassessment, autonomous computational ecosystems continuously monitor changes in tumor biology, therapeutic response, physiological status, toxicity, and recurrence risk while generating updated evidence-based recommendations throughout the patient's clinical journey.

These adaptive computational capabilities establish real-time clinical intelligence as a cornerstone of next-generation personalized oncology.[18]

9. Personalized Therapeutic Decision-Making

One of the most clinically significant applications of autonomous precision oncology is individualized therapeutic optimization through comprehensive integration of molecular biology, imaging phenotypes, histopathological characteristics, laboratory biomarkers, wearable physiological monitoring, medication history, and longitudinal clinical trajectories. Foundation AI models continuously predict responsiveness to chemotherapy, targeted therapy, endocrine therapy, immunotherapy, radiation therapy, surgery, and multimodal treatment combinations while adapting therapeutic recommendations according to evolving patient biology, treatment response, toxicity profiles, and real-world clinical outcomes. These adaptive computational systems establish a continuously learning framework for autonomous precision oncology capable of improving patient outcomes throughout the cancer care continuum.[19][20]

10. Intelligent Clinical Decision Support

Autonomous precision oncology provides the computational infrastructure for next-generation clinical decision-support systems capable of integrating heterogeneous biomedical information into comprehensive patient-centered recommendations. Rather than interpreting radiological imaging, digital pathology, molecular diagnostics, laboratory investigations, wearable physiological monitoring, medication history, physician documentation, patient-reported outcomes, and evidence-based clinical guidelines independently, foundation AI models synthesize these diverse biomedical information sources into unified computational representations supporting multidisciplinary oncology practice.[21]

Interactive clinical dashboards generate individualized diagnostic summaries, multimodal biomarker analyses, digital twin simulations, therapeutic recommendations, toxicity estimates, recurrence probabilities, disease progression forecasts, and survival predictions while facilitating collaboration among oncologists, radiologists, pathologists, surgeons, radiation oncologists, molecular biologists, pharmacists, nurses, genetic counselors, and computational scientists. These intelligent systems improve workflow efficiency, strengthen multidisciplinary communication, reduce fragmentation of biomedical information, and promote evidence-based personalized cancer management throughout the cancer care continuum.

11. Continuous Learning and Autonomous Adaptation

A defining characteristic of autonomous precision oncology is its ability to continuously evolve as new biomedical information becomes available. Artificial intelligence incorporates serial imaging examinations, computational pathology, circulating tumor DNA, laboratory biomarkers, wearable physiological monitoring, medication adherence, patient-reported outcomes, and real-world clinical evidence into adaptive computational frameworks capable of continuously refining predictive accuracy throughout the patient's clinical journey.[22]

Continual learning algorithms enable incremental refinement of computational knowledge without catastrophic forgetting of previously acquired information, while reinforcement learning optimizes therapeutic recommendations through iterative evaluation of treatment outcomes. Agentic AI systems further coordinate evidence retrieval, diagnostic reasoning, workflow automation, treatment planning, longitudinal disease surveillance, and multidisciplinary communication with minimal manual intervention.

This adaptive computational paradigm transforms oncology into a continuously learning healthcare ecosystem capable of supporting real-time personalized precision medicine.

12. Federated Autonomous Oncology Ecosystems

Development of highly generalizable autonomous precision oncology platforms requires access to diverse biomedical datasets representing multiple healthcare systems, imaging platforms, pathology laboratories, molecular technologies, treatment protocols, and patient populations. Federated learning enables collaborative development of foundation AI models while preserving patient privacy and institutional governance through decentralized computational training.[23]

Participating healthcare institutions independently train local models using radiological imaging, digital pathology, genomics, transcriptomics, laboratory investigations, wearable monitoring, liquid biopsy, electronic health records, and longitudinal clinical records while securely exchanging encrypted model parameters rather than identifiable patient information. This collaborative learning strategy substantially improves algorithm robustness, fairness, external validity, and generalizability across diverse healthcare environments.

Federated autonomous oncology ecosystems therefore establish international computational oncology networks capable of accelerating scientific discovery, improving equitable access to precision medicine, and supporting global cancer research while maintaining responsible biomedical data stewardship.

13. Explainability, Validation, and Ethical Governance

Successful implementation of autonomous precision oncology requires transparent, interpretable, reproducible, and rigorously validated computational systems capable of supporting clinician confidence, patient trust, and regulatory approval. Explainable artificial intelligence (XAI) enables clinicians to understand computational reasoning through attention visualization, saliency maps, SHAP (Shapley Additive Explanations), feature attribution analysis, uncertainty estimation, and counterfactual explanations identifying the imaging, molecular, pathological, physiological, and clinical variables responsible for predictive outputs.[24]

Clinical deployment additionally requires standardized multimodal datasets, interoperable computational infrastructure, prospective multicenter validation, external benchmarking, cybersecurity safeguards, continuous monitoring for algorithmic bias, and compliance with evolving international regulatory frameworks governing AI-enabled healthcare technologies.

Responsible implementation further depends upon patient privacy, informed consent, transparency, accountability, equitable access, responsible data governance, and continuous post-deployment surveillance to ensure trustworthy integration of autonomous computational systems into routine oncology practice.

14. Emerging Technologies and Future Convergence

The future of autonomous precision oncology will be driven by the convergence of multimodal foundation models, multimodal large language models, agentic artificial intelligence, graph neural networks, reinforcement learning, federated learning, digital twins, spatial multi-omics, liquid biopsy, quantum computing, robotics, Internet of Medical Things (IoMT), cloud-native healthcare infrastructure, and autonomous clinical reasoning systems.[25]

These emerging technologies will continuously integrate molecular biology, radiological imaging, digital pathology, laboratory medicine, wearable physiological monitoring, environmental exposures, electronic health records, biomedical literature, and real-world clinical outcomes into unified computational ecosystems capable of autonomous reasoning, adaptive therapeutic optimization, intelligent clinical trial matching, precision prevention, personalized survivorship management, and continuous evidence synthesis.

Such technological convergence is expected to redefine oncology as an intelligent, adaptive, and continuously evolving healthcare discipline.

15. Future Perspectives

Future autonomous precision oncology ecosystems will progressively evolve beyond isolated decision-support systems toward comprehensive intelligent healthcare platforms capable of continuously modeling individual patient biology throughout diagnosis, treatment, recurrence, survivorship, and long-term follow-up.[26]

Digital twins will increasingly simulate alternative therapeutic pathways, foundation AI models will autonomously incorporate newly published biomedical evidence, multimodal learning systems will integrate previously inaccessible biological modalities, and intelligent clinical agents will coordinate diagnostic workflows, multidisciplinary communication, patient education, clinical documentation, and precision treatment planning.

These integrated computational ecosystems are expected to support predictive, preventive, personalized, participatory, and continuously optimized oncology on an unprecedented global scale.

16. Discussion

Autonomous precision oncology represents one of the most significant paradigm shifts in computational cancer medicine by integrating foundation AI models, digital twins, multimodal learning, molecular biology, imaging intelligence, computational pathology, and longitudinal clinical reasoning into unified computational ecosystems capable of supporting comprehensive personalized cancer care. Unlike conventional artificial intelligence systems developed for isolated predictive tasks, these intelligent frameworks simultaneously analyze molecular biology, tissue architecture, radiological imaging, laboratory biomarkers, physiological monitoring, environmental influences, and longitudinal clinical trajectories to generate holistic computational representations of evolving cancer biology.[27]

Applications spanning computational pathology, radiogenomics, biomarker discovery, digital twins, precision immunotherapy, adaptive therapeutics, continuous learning, federated collaboration, digital health, survivorship management, and intelligent clinical decision support demonstrate the extraordinary potential of autonomous computational intelligence to redefine future oncology. Nevertheless, successful implementation requires continued advances in multimodal data harmonization, explainable artificial intelligence, interoperability, computational infrastructure, cybersecurity, regulatory science, ethical governance, and sustained multidisciplinary collaboration.

As biomedical knowledge and healthcare data continue to expand exponentially, autonomous precision oncology ecosystems are expected to become the central computational infrastructure supporting personalized cancer medicine worldwide.

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv14i1220

17. Conclusion

Autonomous precision oncology is transforming personalized cancer medicine by integrating foundation AI models, digital twins, radiological imaging, digital pathology, multi-omics, laboratory biomarkers, wearable technologies, electronic health records, and longitudinal clinical intelligence into unified computational ecosystems capable of supporting accurate diagnosis, biomarker discovery, prognostic prediction, therapeutic optimization, adaptive disease monitoring, and individualized clinical decision-making throughout the cancer care continuum.[28]

Advances in transformer architectures, multimodal learning, graph neural networks, self-supervised learning, federated learning, reinforcement learning, digital twins, multimodal large language models, agentic AI, and generative artificial intelligence are expected to further strengthen autonomous oncology ecosystems, enabling increasingly accurate molecular characterization, predictive clinical intelligence, adaptive therapeutics, continuous disease surveillance, and continuously personalized oncology care.[29]

Although important scientific, technical, ethical, regulatory, and implementation challenges remain, sustained collaboration among oncologists, radiologists, pathologists, molecular biologists, biomedical engineers, computer scientists, healthcare organizations, policymakers, industry partners, and regulatory agencies will accelerate the responsible implementation of autonomous precision oncology. These innovations have the potential to improve patient outcomes, enhance healthcare efficiency, reduce disparities in cancer care, accelerate translational research, and establish a new era of intelligent, adaptive, and continuously learning precision oncology worldwide.[30]

References

1. Meric-Bernstam, F. et al. (2023) ‘Enhancing Precision Oncology Through Multimodal Data Integration’, Nature Reviews Clinical Oncology, 20(4), pp. 267-283.
2. Dr. RajathaMaradiHemanth Kumar (Author), MULTIMODAL FOUNDATION AI MODELS IN PRECISION ONCOLOGY: INTEGRATING RADIOMICS, PATHOMICS, MULTI-OMICS, AND CLINICAL INTELLIGENCE SYSTEMS, Vol. 52 No. 4 (2024): October–December 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/343, DOI: https://doi.org/10.46121/pspc.52.4.16
3. Joshi, A. et al. (2023) ‘Multimodal Learning for Precision Oncology: Beyond Single-modality Analysis’, npj Precision Oncology, 7(1), p. 28.
4. Dr. Latha Kiran Krishna Rajendran (Author), Genomic Profiling: Utilizing Multi-Omics Data to Identify Potential Therapeutic Targets and Resistance Markers, Vol. 52 No. 4 (2024): October–December 2024, Power System Protection and Control, ISSN: 1674-3415, Article URL: https://pspac.info/index.php/dlbh/article/view/312, DOI: https://doi.org/10.46121/pspc.52.4.13.
5. Huang, S.C. et al. (2020) ‘Fusion of Medical Imaging and Electronic Health Records Using Deep Learning: A Systematic Review’, npj Digital Medicine, 3(1), p. 136.
6. Dr. RajathaMaradiHemanth Kumar (Author), PAN-System Cancer Intelligence: Integrating Blood, Immune, Microbiome, and Tumor Microenvironment Data Using Foundation Models, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/389, DOI: https://doi.org/10.46121/pspc.51.4.8
7. Lambin, P. et al. (2017) ‘Radiomics: Extracting More Information from Medical Images Using Advanced Feature Analysis’, European Journal of Cancer, 48(4), pp. 441-446.
8. Zwanenburg, A. et al. (2023) ‘The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping’, Radiology, 308(2), e221422.
9. Chen, R.J. et al. (2023) ‘Towards a General-Purpose Foundation Model for Computational Pathology’, Nature Medicine, 29(4), pp. 850-862.
10. Kather, J.N. et al. (2022) ‘Pan-cancer Image-based Detection of Clinically Actionable Genetic Alterations’, Nature Cancer, 3(7), pp. 789-799.

11. Chaudhary, K. et al. (2021) 'Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer', Clinical Cancer Research, 27(5), pp. 1248-1259.
12. Cancer Genome Atlas Research Network (2013) 'The Cancer Genome Atlas Pan-Cancer Analysis Project', Nature Genetics, 45(10), pp. 1113-1120.
13. Huang, S.C. et al. (2021) 'Self-supervised Learning for Medical Image Classification: A Systematic Review', IEEE Transactions on Medical Imaging, 40(8), pp. 2021-2037.
14. Moor, M. et al. (2023) 'Foundation Models for Generalist Medical Artificial Intelligence', Nature, 616(7956), pp. 259-265.
15. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31–46. Doi:10.1158/2159-8290.CD-21-1059.
16. Singhal K, Azizi S, Tu T, et al. Large language models encode clinical knowledge. Nature. 2023;620(7972):172–180. Doi:10.1038/s41586-023-06291-2.
17. Xu H, Usuyama N, Bagga J, et al. A whole-slide foundation model for digital pathology from real-world data. Nature. 2024;630(8015):181–188. Doi:10.1038/s41586-024-07441-w.
18. Moor M, Banerjee O, Abad ZSH, et al. Foundation models for generalist medical artificial intelligence. Nature. 2023;616(7956):259–265. Doi:10.1038/s41586-023-05881
19. Bommasani R, Hudson DA, Adeli E, et al. On the opportunities and risks of foundation models. arXiv. 2021. Doi:10.48550/arXiv.2108.07258.
20. Dosovitskiy A, Beyer L, Kolesnikov A, et al. An image is worth 16×16 words: transformers for image recognition at scale. arXiv. 2020. Doi:10.48550/arXiv.2010.11929.
21. Dr. Ohmini Krishnamurthy Rajendran (Author), AI-BASED RADIOGENOMIC MODELS FOR PREDICTING IMMUNOTHERAPY RESPONSE IN SOLID TUMORS, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/321 , DOI: https://doi.org/10.46121/pspc.51.4.4
22. Dr. Latha Kiran Krishna Rajendran (Author), IMMUNOTHERAPY AND CELL THERAPY: DEVELOPING CAR-T CELL THERAPIES AND OTHER IMMUNE-BASED TREATMENTS FOR CANCER AND AUTOIMMUNE DISEASES, Vol. 51 No. 2 (2023): April-June 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/304 , DOI: https://doi.org/10.46121/pspc.51.2.7
23. Chakraborty, S. et al. (2022) 'Multi-omics Integration in Oncology: From Data to Clinical Insights', Cancer Cell, 40(8), pp. 805-823.
24. Dr. Ohmini Krishnamurthy Rajendran (Author), FEDERATED RADIOLOGY AI MODELS FOR MULTI-INSTITUTIONAL CANCER DIAGNOSIS WITHOUT DATA SHARING, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/323 , DOI: https://doi.org/10.46121/pspc.51.4.5
25. Dr. Latha Kiran Krishna Rajendran (Author), MECHANISMS DRIVING IMMUNOTHERAPY RESISTANCE IN COLORECTAL CANCER LIVER METASTASES, Vol. 52 No. 1 (2024): January-March 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/303 , DOI: https://doi.org/10.46121/pspc.52.1.5
26. Dr. Ohmini Krishnamurthy Rajendran (Author), FOUNDATION MODEL-DRIVEN PRECISION ONCOLOGY: INTEGRATING MULTI-OMICS, RADIOLOGY, AND CLINICAL DATA FOR PREDICTIVE CANCER CARE, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/324 , DOI: https://doi.org/10.46121/pspc.52.2.14
27. Dr. Latha Kiran Krishna Rajendran (Author), CANCER NANOMEDICINE: UTILIZING THE ENHANCED PERMEABILITY AND RETENTION (EPR) EFFECT TO DELIVER HIGH PAYLOADS OF CHEMOTHERAPEUTIC AGENTS DIRECTLY TO TUMOR SITES, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/311, DOI: https://doi.org/10.46121/pspc.52.2.12

Volume 14, Issue-12
December, 2024, P20
ISSN: 2319-9253

28. Dr. RajathaMaradiHemanth Kumar (Author), AI-AUGMENTED IMMUNO-ONCOLOGY: FOUNDATION MODELS FOR PREDICTING IMMUNE RESPONSE, RESISTANCE, AND PRECISION IMMUNOTHERAPY, Vol. 52 No. 2 (2024): April–June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/345, DOI: https://doi.org/10.46121/pspc.52.2.18
29. Dr. RajathaMaradiHemanth Kumar (Author), AI-Driven Liquid Biopsy Systems for Early Cancer Detection and Personalized Oncology, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/388, DOI: https://doi.org/10.46121/pspc.51.4.7
30. Dr. Ohmini Krishnamurthy Rajendran (Author), SELF-SUPERVISED MULTIMODAL LEARNING FOR EARLY CANCER DETECTION ACROSS IMAGING AND GENOMICS, Vol. 52 No. 4 (2024): October-December 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/325, DOI: https://doi.org/10.46121/pspc.52.4.14